Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
Seven Days
Nonprofit challenges Gilead’s patents on sofosbuvir
Nonprofit Group I-MAK Files IPR Petitions Seeking to Invalidate Hepatitis C Drug Patent
Trending News Today: Gilead HCV Drug Patents Challenged
Gilead’s Lucrative Hep C Patents Face PTAB Assault
Gilead faces challenge to U.S. hepatitis C patents from advocacy group
Consumer group challenges Gilead patents on hepatitis C drug
Gilead’s Patents on Hepatitis C Drug Challenged by Consumer Group
Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty
First-Ever U.S. Patent Challenges Dispute Gilead’s Monopoly on Hepatitis C Drugs that Blocks Millions from Treatment